IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 66.74

Change

-0.27 (-0.40)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-22 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.32 (-0.22%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.03 (-0.04%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.34 (-0.31%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

-0.09 (-0.10%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.02 (-0.09%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.22 (+0.68%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.07 (+0.07%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.17 (+0.56%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.42 (+0.68%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.35 (+1.55%)

USD 8.55M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.55% 29% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.55% 29% F 44% F
Trailing 12 Months  
Capital Gain 5.41% 52% F 48% F
Dividend Return 1.47% 88% B+ 23% F
Total Return 6.87% 57% F 40% F
Trailing 5 Years  
Capital Gain 24.66% 48% F 62% D
Dividend Return 8.84% 95% A 27% F
Total Return 33.50% 62% D 57% F
Average Annual (5 Year Horizon)  
Capital Gain 4.27% 48% F 48% F
Dividend Return 5.65% 57% F 45% F
Total Return 1.38% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.38% 71% C- 66% D+
Risk Adjusted Return 36.73% 67% D+ 51% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike